SALEM, NH--(Marketwired - Sep 9, 2015) - ProPhotonix Limited (
ProPhotonix introduces COBRA Cure™ FX UV LED Lamp with IntelliSense™ Smart Sensing Technology
Stackable Design, Field-Replaceable Window, Multiple Optical Output Options, Innovative sensing software
(Salem, New Hampshire, September 9, 2015) ProPhotonix Limited (
LED illumination offers significant benefits versus traditional UV lamps including longer illuminator lifetimes, high stability light output, precise control, thermal management, ozone-free, heavy metal free, and lower total cost of ownership.
The COBRA Cure FX unique design includes a field-replaceable exit window. In certain operating environments, materials can build-up over time on the outer surface of the window which reduces the intensity of the light causing a degradation of system performance. Without this unique design, the operator must manually clean the emitter window which causes machine down time but also causes abrasion damage to the window thus reducing the light's effectiveness during operation. The field-replaceable window allows fast and efficient changes by non-technical personnel. This innovative patent pending design is easy to use, requires no special tools for window replacement, and ensures that the window is secure during operation, thus minimizing system downtime.
COBRA Cure FX also incorporates IntelliSense, a patent pending new smart sensing technology which provides precise output control, operational intelligence and "Plug & Play" integration for end users. Sensing features include: real-time thermal monitoring, a necessity ensuring proper system operation; intensity monitoring, providing operating irradiance and efficiency data; lifetime prediction of the lamp, reliability and longevity estimates; and numerous health & safety features. IntelliSense is the state of the art sensing capability in illumination.
Commenting on the COBRA Cure FX launch, Tim Losik, CEO and President of ProPhotonix, said:
"Over the past two years we have assessed various markets and product features and have developed a product strategy focusing on large markets complemented by our design capabilities. To this end, we are concentrating our engineering talents in a couple of specific market areas which we believe are poised for fast market expansion. One of these is the ultra violet LED and laser market, addressing various applications including: printing, curing, 3D printing, bio-luminescence, medical microscopy, and other applications. Market research shows that the 2014 market size for UV LED applications was approximately $90 million with projected growth to $500 million by 2019, a compound average annual growth rate of nearly 40%.
"This product redefines the capabilities of the world's best UV LED lamps by increasing the operational capabilities and improving customer ease of use. As this product line develops, we intend to introduce more exciting enhancements and capabilities for users. To protect our intellectual property rights within this product, United States Patent Applications have recently been filed covering several of the unique features of the product design including the capabilities of IntelliSense. We will continue to file patent applications, where appropriate, to protect our expanding intellectual property portfolio."
For more information about ProPhotonix' COBRA Cure FX, visit http://www.prophotonix.com/products/UV-Solutions/
Contact:
| ProPhotonix Limited Tim Losik |
sales@prophotonix.com Tel: +1 603 893 8778 |
| N+1 Singer Ben Wright/ Richard Salmond |
Tel: +44 (0) 207 496 3000 |
| Nominated Adviser and Broker | |
About ProPhotonix
ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of LED illumination systems and laser diode modules for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Opnext), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, ultra violet applications, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.
This information is provided by RNS
The company news service from the London Stock Exchange
Contact Information:
RNS
Customer Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com